ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE - Generic Drug Details

What are the generic drug sources for estradiol cypionate; testosterone cypionate and what is the scope of freedom to operate?

Estradiol cypionate; testosterone cypionate is the generic ingredient in two branded drugs marketed by Pharmacia And Upjohn and Watson Labs, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Summary for ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Clinical Trials:	2
DailyMed Link:	ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE at DailyMed

Recent Clinical Trials for ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sidney Kimmel Comprehensive Cancer Center	Phase 2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2
VA Office of Research and Development	Phase 1

See all ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

G03BA	3-oxoandrosten (4) derivatives
G03B	ANDROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

G03CA	Natural and semisynthetic estrogens, plain
G03C	ESTROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE	estradiol cypionate; testosterone cypionate	INJECTABLE;INJECTION	085603-001	Mar 13, 1986		DISCN	No	No
Pharmacia And Upjohn	DEPO-TESTADIOL	estradiol cypionate; testosterone cypionate	INJECTABLE;INJECTION	017968-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Estradiol Cypionate and Testosterone Cypionate Market Dynamics, Patent Status, and Financial Trajectory

Last updated: September 12, 2026

Estradiol cypionate and testosterone cypionate are mature injectable hormones with fundamentally different commercial profiles. Testosterone cypionate has an active U.S. generic market supported by continuing demand for testosterone-replacement therapy. Estradiol cypionate is a niche or limited-availability product with minimal publicly visible manufacturer revenue and substantially greater supply risk.

Neither product has a meaningful period of remaining brand exclusivity based on its original drug patents. Commercial performance is driven by formulation availability, manufacturing capacity, prescribing trends, reimbursement, controlled-substance compliance for testosterone, and the growth of compounding pharmacies.

What is the current market position of estradiol cypionate?

Estradiol cypionate is a long-acting injectable ester of estradiol. The historical U.S. reference product is Depo-Estradiol, an intramuscular injection associated with Pfizer. The product was approved for estrogen-deficiency indications, including vasomotor symptoms, vulvar and vaginal atrophy, female hypogonadism, and selected estrogen-deficiency conditions.[1]

The U.S. commercial market is small compared with oral estradiol, transdermal estradiol, estradiol valerate injection, and testosterone products. The principal market constraints are:

• Limited commercial availability of an approved estradiol cypionate injection.
• Physician preference for transdermal or oral estradiol.
• Greater availability of estradiol valerate in gender-affirming care.
• Reliance on specialty pharmacies and compounding pharmacies when commercial supply is unavailable.
• Low manufacturing scale and limited incentive to maintain a dedicated injectable product.

Estradiol cypionate demand is concentrated in hormone-replacement therapy, selected menopause treatment, hypogonadism-related estrogen deficiency, and gender-affirming hormone therapy. The gender-affirming care segment has increased demand for injectable estrogen generally, but that demand does not necessarily translate into higher revenue for estradiol cypionate because estradiol valerate is often the more accessible injectable ester.

Is Depo-Estradiol still marketed in the United States?

The historical Depo-Estradiol product has been listed as discontinued in U.S. drug-information and regulatory databases. A discontinued listing does not by itself establish a safety withdrawal. It indicates that the product is no longer actively marketed under the relevant commercial listing.[2]

The practical result is that estradiol cypionate has limited branded-market visibility. Current patient access may depend on compounded preparations, specialty distribution, or non-U.S. supply channels. Commercial status can differ by jurisdiction and by package presentation.

What is the current market position of testosterone cypionate?

Testosterone cypionate is a long-acting injectable androgen used primarily for testosterone replacement in men with documented hypogonadism. The reference product is Depo-Testosterone, originally associated with Pfizer. Generic testosterone cypionate injections are available in multiple vial strengths and package sizes, subject to manufacturer and supply conditions.[3]

The product has a much larger and more durable market than estradiol cypionate because:

1. Testosterone-replacement therapy has a large established patient population.
2. Intramuscular testosterone cypionate is familiar to prescribers and patients.
3. The drug is inexpensive relative to branded topical and long-acting testosterone products.
4. Self-injection and clinic-administered injection models support recurring demand.
5. Generic manufacturers can produce a mature formulation without developing a novel delivery platform.

Testosterone cypionate is a Schedule III controlled substance in the United States. That classification increases compliance and distribution costs but also creates barriers for some smaller entrants.[4]

Which companies compete in testosterone cypionate?

Competition is primarily generic and has included manufacturers such as Hikma Pharmaceuticals, Cipla, Perrigo, and other approved suppliers depending on the period and product presentation. Pfizer's Depo-Testosterone remains the reference brand, while generic suppliers compete on contract access, wholesaler availability, vial sizes, and price.

Manufacturer participation changes over time. A supplier may remain approved but have no active commercial inventory, or may supply only selected strengths. Therefore, approval status and actual market share are separate issues.

How many patents protect estradiol cypionate and testosterone cypionate?

The original product patent estates for both drugs are effectively exhausted. These are old small-molecule injectable products, and the key commercial barriers are no longer basic composition patents.

Product	Reference product	Principal U.S. market structure	Remaining original patent leverage
Estradiol cypionate	Depo-Estradiol	Limited or discontinued branded availability; compounding and alternative estrogen products	No meaningful original-product exclusivity
Testosterone cypionate	Depo-Testosterone	Active generic injectable market plus branded product	No meaningful original-product exclusivity

The relevant intellectual-property risks are more likely to arise from:

• A new delivery system.
• A prefilled syringe or autoinjector.
• A sustained-release formulation.
• A combination product.
• A manufacturing process with measurable cost or quality advantages.
• A new method of use tied to a specific patient population or dosing regimen.

Old patents covering the active ingredients or conventional ester formulations do not provide a practical basis for blocking ordinary generic injections.

When do estradiol cypionate and testosterone cypionate lose exclusivity?

Both products lost meaningful U.S. market exclusivity decades ago. Their commercial histories predate the modern Hatch-Waxman framework for most practical purposes.

Testosterone cypionate has no current brand-only period that prevents ANDA competition. Generic approval and market entry are controlled by FDA requirements for pharmaceutical equivalence, bioequivalence where applicable, sterility, manufacturing quality, and controlled-substance compliance.[5]

Estradiol cypionate likewise has no practical remaining exclusivity tied to the original product. The more important issue is whether an applicant can justify a commercial product at a sufficiently large scale to support FDA compliance, pharmacovigilance, sterile manufacturing, and distribution.

What is the Orange Book status of these products?

The FDA Orange Book is the primary source for approved drug products, therapeutic-equivalence evaluations, patents, and regulatory exclusivity information.[5]

For testosterone cypionate, the Orange Book framework is commercially important because generic products can be evaluated against the reference listed drug. The presence of an approved generic does not guarantee uninterrupted supply, and Orange Book listing does not indicate current market share.

For estradiol cypionate, the historical reference product's discontinued status limits the practical importance of Orange Book competition. The key commercial question is not whether a patent blocks entry, but whether an applicant can establish a current regulatory and supply pathway for a relatively small market.

No current blockbuster-style Orange Book patent strategy is associated with either molecule.

Are there Paragraph IV challenges for these drugs?

Paragraph IV litigation is not a material current market driver for conventional estradiol cypionate or testosterone cypionate injections.

A Paragraph IV certification challenges the validity, enforceability, or infringement of a listed patent in an ANDA pathway. Such disputes are common for newer branded drugs with active formulation, method-of-use, or delivery patents. They are less relevant to old hormone esters whose core product patents have expired.

A new branded formulation could create Paragraph IV exposure if it listed patents covering:

• A novel depot system.
• A controlled-release injectable matrix.
• A specific concentration or dosing schedule.
• A device or administration method.
• A combination treatment.

The conventional generic injections do not depend on a live patent thicket.

What formulation patents protect these products?

The basic injectable formulations are mature. Commercial differentiation is more likely to come from delivery and usability than from the active ingredient.

Estradiol cypionate formulation opportunities

Potentially defensible products could include:

• A ready-to-use prefilled syringe.
• A lower-volume or higher-concentration formulation.
• A reduced-irritation vehicle.
• A sustained-release formulation with longer dosing intervals.
• A sterile product with improved cold-chain or room-temperature stability.
• A device designed for home administration.

The market opportunity is constrained by the small installed base and competition from estradiol valerate, transdermal patches, gels, tablets, and compounded products.

Testosterone cypionate formulation opportunities

Potential innovation areas include:

• Autoinjectors and prefilled syringes.
• Lower-pain subcutaneous injection formats.
• Extended dosing intervals.
• Reduced-volume formulations.
• Digital adherence and injection-support systems.
• Combination products that address hypogonadism management.

Testosterone cypionate itself is vulnerable to price competition. A new product would need a clear convenience, adherence, safety, or pharmacokinetic benefit to command a premium.

What is the FDA regulatory status of the two drugs?

Both products are established small-molecule injectable therapies, not biologics. Biosimilar regulation is therefore not applicable.

Regulatory issue	Estradiol cypionate	Testosterone cypionate
Drug class	Estrogen ester	Androgen ester
FDA pathway for conventional generic	ANDA or applicable abbreviated pathway	ANDA
Biosimilar exposure	None	None
Sterility requirement	Yes	Yes
Controlled substance	No	Schedule III
Key regulatory risk	Product availability and sterile manufacturing	Controlled-substance compliance, supply and manufacturing
Main substitutes	Oral/transdermal estradiol, estradiol valerate	Testosterone enanthate, topical testosterone, oral testosterone undecanoate, long-acting testosterone undecanoate

Testosterone products also face heightened regulatory scrutiny around cardiovascular risk communications, abuse potential, prescribing controls, and appropriate diagnosis of hypogonadism.[6]

How strong is the patent estate for estradiol cypionate versus testosterone cypionate?

The patent strength of both legacy products is low. The commercial strength of testosterone cypionate is higher because demand and manufacturing infrastructure are stronger, not because its patent estate is stronger.

Factor	Estradiol cypionate	Testosterone cypionate
Original composition-patent protection	Exhausted	Exhausted
Active formulation-patent barrier	Limited	Limited
Generic price pressure	Moderate where supply exists	High
Supply-chain depth	Thin	Deeper
Prescribing base	Niche	Broad
Substitution risk	High	Moderate to high
Premium-pricing potential	Low for legacy product	Low for legacy product; higher for novel delivery
IP value of new formulation	Potentially meaningful	Potentially meaningful

Testosterone cypionate has stronger commercial defensibility through scale and recurring demand. Estradiol cypionate has greater scarcity value if a supplier can establish reliable FDA-compliant availability, but scarcity alone does not create durable exclusivity.

What generic entry risks exist?

Estradiol cypionate

The principal risk is not a wave of conventional generic launches. It is substitution by other estradiol products and compounded preparations. A new commercial supplier could enter a relatively open patent field but face:

• Small market size.
• Limited reimbursement leverage.
• Sterile injectable manufacturing costs.
• Uncertain pharmacy demand.
• Competition from estradiol valerate.
• Potential regulatory scrutiny of compounded hormone products.

Testosterone cypionate

Generic entry is already established. The major risks are price erosion, wholesaler substitution, manufacturing interruptions, and competition from other testosterone delivery systems.

Generic products can gain share rapidly when they maintain supply and offer broad wholesaler coverage. Conversely, a manufacturing disruption can shift demand to branded Depo-Testosterone, alternative testosterone esters, or compounded products.

What are the revenue and financial trajectories?

Public companies generally do not report standalone revenue for estradiol cypionate or testosterone cypionate. The products are usually embedded in broader generic, branded, or specialty-pharmaceutical segments. Product-level revenue estimates from commercial databases are not publicly audited.

Estradiol cypionate financial trajectory

The financial trajectory is best characterized as low-volume and supply-constrained:

• Historical branded revenue has declined with discontinuation or reduced availability.
• Current revenue is fragmented across limited commercial supply and compounding channels.
• There is little evidence of a large branded revenue pool.
• A new entrant would likely compete for a niche market rather than recover blockbuster development costs.
• Revenue could increase from restored supply, but the ceiling is limited by alternative estrogen products.

The strongest business case would be a low-cost, reliable injectable platform that also supports additional hormone products.

Testosterone cypionate financial trajectory

Testosterone cypionate has a more durable revenue base:

• Demand is supported by chronic testosterone-replacement therapy.
• Generic prices are low, limiting per-unit margins.
• Volume is more stable than price.
• Brand revenue is pressured by generic substitution.
• Premium revenue is migrating toward topical, oral, long-acting, and device-enabled products.
• Supply reliability can temporarily improve manufacturer economics.

The product is a cash-flow and volume product rather than an exclusivity product. The financial value lies in manufacturing scale, procurement access, and portfolio breadth.

What licensing deals affect these products?

No major, widely disclosed licensing transaction currently defines the commercial market for conventional estradiol cypionate or testosterone cypionate.

Licensing value is more likely to arise around:

• Novel injection devices.
• Long-acting delivery platforms.
• Contract manufacturing arrangements.
• Regional commercialization rights.
• Compounded or specialty-pharmacy distribution.
• Combination products with proprietary delivery technology.

For testosterone cypionate, licensing a device or sustained-release technology could support premium pricing. For estradiol cypionate, a licensing deal would need to solve both product availability and market scale.

What patent litigation affects estradiol cypionate and testosterone cypionate?

There is no prominent current patent-litigation pattern comparable to litigation surrounding major branded oncology, immunology, or metabolic drugs. Conventional product competition is largely governed by generic approval, manufacturing capacity, and commercial distribution.

Litigation risk would increase if a company launched:

• A patented long-acting formulation.
• A device-linked product.
• A method-of-use product with an Orange Book-listed patent.
• A product relying on a new concentration or dosing schedule.
• A formulation with commercially meaningful pharmacokinetic differentiation.

Absent those features, patent litigation is unlikely to be the main market-access risk.

How does estradiol cypionate compare with testosterone cypionate?

Metric	Estradiol cypionate	Testosterone cypionate
Market scale	Small and fragmented	Established and recurring
U.S. branded availability	Limited or discontinued	Depo-Testosterone remains the reference brand
Generic intensity	Limited conventional competition	High
Regulatory complexity	Sterile injectable requirements	Sterile injectable plus Schedule III controls
Primary demand driver	Niche estrogen therapy and injectable preference	Chronic testosterone replacement
Main competitor	Estradiol valerate and noninjectable estradiol	Testosterone enanthate, topical products, oral testosterone
Patent barrier	Low	Low
Revenue outlook	Flat to niche recovery	Stable volume with price pressure
Best commercial strategy	Reliable supply and specialty distribution	Scale, cost control, and delivery innovation

What generic launch scenarios are most likely?

Estradiol cypionate

The most plausible scenario is a limited commercial launch by a specialty or generic manufacturer, potentially supported by a contract sterile-manufacturing partner. A successful product would need dependable supply and a distribution strategy focused on endocrinology, menopause care, gender-affirming care, and specialty pharmacies.

Testosterone cypionate

The likely scenario is continued multi-source generic competition with periodic market-share shifts caused by supply interruptions, contracting changes, and price competition. New entrants face a lower patent barrier but a higher commercial hurdle because established suppliers already serve the market.

What geographic coverage exists?

The United States is the most commercially visible market for testosterone cypionate because of its established prescribing base and generic infrastructure. Availability varies by country because testosterone regulation, reimbursement, approved esters, and controlled-substance rules differ.

Estradiol cypionate has narrower geographic coverage and may be unavailable as an approved commercial product in some jurisdictions. Estradiol valerate and noninjectable estradiol products are more common international alternatives.

Geographic expansion would require country-specific approvals, controlled-substance or hormone regulations, local pharmacovigilance, and reimbursement access. Existing U.S. approval does not create automatic foreign market access.

Key Takeaways

• Testosterone cypionate is a mature, high-volume generic injectable with durable demand and low patent protection.
• Estradiol cypionate is a niche, supply-constrained product with limited visible branded-market activity.
• Neither product has meaningful original-patent exclusivity remaining.
• Conventional generic entry is not primarily blocked by patents.
• Testosterone cypionate revenue is likely to remain volume-driven but exposed to generic price erosion.
• Estradiol cypionate has limited revenue scale but could have strategic value if a manufacturer restores reliable commercial supply.
• New formulation, device, and delivery patents are more commercially relevant than legacy composition patents.
• Neither product has biosimilar risk because both are small-molecule drugs.
• The main commercial barriers are sterile manufacturing, supply reliability, reimbursement, distribution, and product substitution.

FAQs

Is testosterone cypionate still profitable for generic manufacturers?

Yes, but profitability depends on manufacturing scale, supply reliability, purchasing contracts, and price discipline. The product has recurring demand but limited pricing power.

Can a company obtain exclusivity for a new estradiol cypionate injection?

Potentially, but exclusivity would need to arise from a novel formulation, device, delivery system, or qualifying clinical use rather than the old active ingredient alone.

Is estradiol cypionate interchangeable with estradiol valerate?

They are different estradiol esters and are not automatically interchangeable. Dosing, pharmacokinetics, product concentration, labeling, and local regulatory requirements must be evaluated.

Does testosterone cypionate compete with testosterone undecanoate?

Yes. Testosterone undecanoate offers a longer dosing interval in some products, while testosterone cypionate is generally less expensive and more familiar for self-injection or clinic administration.

Are compounded versions a major threat to commercial estradiol cypionate?

They can be, particularly when an approved commercial product is unavailable. Compounding may support access but does not provide the same regulatory status, manufacturing scale, or distribution model as an FDA-approved product.

References

1. U.S. Food and Drug Administration. (n.d.). Depo-Estradiol prescribing information. FDA drug labeling database.
2. National Library of Medicine. (n.d.). Estradiol cypionate drug information. DailyMed.
3. U.S. Food and Drug Administration. (n.d.). Depo-Testosterone prescribing information. FDA drug labeling database.
4. U.S. Drug Enforcement Administration. (n.d.). Controlled substance schedules.
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
6. U.S. Food and Drug Administration. (2015). FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging. FDA.